Deborah Knobelman
Director of Finance/CFO bei SENTI BIOSCIENCES, INC.
Vermögen: 49 387 $ am 31.03.2024
Profil
Dr. Deborah A.
Knobelman is a CFO, Treasurer & Head-Corporate Development at Senti Biosciences, Inc. and a Chief Financial Officer & Treasurer at Senti Sub I, Inc. Dr. Knobelman was previously employed as a Chief Financial Officer by GeneriCo LLC, a Chief Business Officer by Ampio Pharmaceuticals, Inc., a Director-Commercial Strategy & Analytics by Pfizer Inc., a Senior Research Analyst by Piper Jaffray & Co. (Broker), a Research Analyst by J.P.
Morgan & Co., Inc. (Old), and a Senior Research Analyst by ThinkEquity Partners.
She received her undergraduate degree from Duke University and a doctorate degree from the University of Pennsylvania Medical Center.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SENTI BIOSCIENCES, INC.
0,29% | 01.02.2024 | 131 000 ( 0,29% ) | 49 387 $ | 31.03.2024 |
Aktive Positionen von Deborah Knobelman
| Unternehmen | Position | Beginn |
|---|---|---|
| SENTI BIOSCIENCES, INC. | Director of Finance/CFO | 01.05.2021 |
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 01.05.2021 |
Ehemalige bekannte Positionen von Deborah Knobelman
| Unternehmen | Position | Ende |
|---|---|---|
GeneriCo LLC
 GeneriCo LLC Pharmaceuticals: GenericHealth Technology GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO. | Director of Finance/CFO | 01.07.2017 |
| AMPIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.04.2012 |
| PFIZER, INC. | Corporate Officer/Principal | 01.08.2011 |
Piper Sandler & Co. (Broker)
 Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Piper Sandler & Co. (Broker) (PSC-Broker) is the full-service brokerage division of Piper Sandler & Co., a financial service firm headquartered in Minneapolis, Minnesota. They are a subsidiary of Piper Sandler Companies (NYSE: PIPR). The firm was founded in 1969 and previously known as Piper Jaffray & Co. They became Piper Sandler & Co. when Piper Jaffray Companies and Sandler O’Neill & Partners, L.P. merged to become Piper Sandler Companies in 2020. PSC-Broker provides brokerage and investment banking services to financial institutions, corporations and other financial investors. Their core focus sectors are Agriculture, renewables & cannabis, Business services, Chemicals & Materials, Consumer, Diversified industrials & services, Energy, Financial services, financial sponsors, Healthcare, and Technology. | Analyst-Equity | 30.06.2007 |
ThinkEquity Partners
 ThinkEquity Partners Investment ManagersFinance Headquartered in San Francisco with additional offices in New York City, Minneapolis, Chicago and Boston, ThinkEquity Partners is a broker/dealer. The firm offers targeted research and investment banking services for institutional investors and corporate clients. They specialize in identifying, analyzing and understanding the technological, macroeconomic and cultural trends that impact key growth verticals, with a particular concentration on healthcare, technology, media/education and business/consumer services. The firm starts with a top-down analysis approach and then allocates resources based on a long-range research roadmap. | Analyst-Equity | 01.08.2004 |
Ausbildung von Deborah Knobelman
| Duke University | Undergraduate Degree |
| University of Pennsylvania Medical Center | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| AMPIO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Piper Sandler & Co. (Broker)
Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Piper Sandler & Co. (Broker) (PSC-Broker) is the full-service brokerage division of Piper Sandler & Co., a financial service firm headquartered in Minneapolis, Minnesota. They are a subsidiary of Piper Sandler Companies (NYSE: PIPR). The firm was founded in 1969 and previously known as Piper Jaffray & Co. They became Piper Sandler & Co. when Piper Jaffray Companies and Sandler O’Neill & Partners, L.P. merged to become Piper Sandler Companies in 2020. PSC-Broker provides brokerage and investment banking services to financial institutions, corporations and other financial investors. Their core focus sectors are Agriculture, renewables & cannabis, Business services, Chemicals & Materials, Consumer, Diversified industrials & services, Energy, Financial services, financial sponsors, Healthcare, and Technology. | Finance |
ThinkEquity Partners
ThinkEquity Partners Investment ManagersFinance Headquartered in San Francisco with additional offices in New York City, Minneapolis, Chicago and Boston, ThinkEquity Partners is a broker/dealer. The firm offers targeted research and investment banking services for institutional investors and corporate clients. They specialize in identifying, analyzing and understanding the technological, macroeconomic and cultural trends that impact key growth verticals, with a particular concentration on healthcare, technology, media/education and business/consumer services. The firm starts with a top-down analysis approach and then allocates resources based on a long-range research roadmap. | Finance |
GeneriCo LLC
GeneriCo LLC Pharmaceuticals: GenericHealth Technology GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO. | Health Technology |
| J.P. Morgan & Co., Inc. (Old) | Finance |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
| Senti Biosciences, Inc. |
